Skip to content

Study · Ex vivo tissue · chicken · 2001

2 results

The effects of triodothyronine and thymulin on avian NK cytolytic activity.

Marsh JA, Merlino PG, Staeheli P

International immunopharmacology1 Sept 2001Cited by 6 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In chicken NK cell cultures, thymulin alone significantly increased cytolytic activity in both K and SLD strains.

    In plain wordsIn lab tests, thymulin alone increased chicken NK cell killing activity in both strains.

    Outcome
    IncreaseNK cytolytic activity
    Study

    chickenn: not reported in source

    K and SLD chicken splenocyte-derived NK cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro thymulin treatments alone significantly enhanced cytolytic activity for NK cells for both K and SLD strains.
  2. 02LabEx vivo tissueActivity measurement

    In chicken NK cell cultures, thymulin increased responsiveness to ChIFN-gamma stimulation.

    In plain wordsIn lab tests, thymulin increased chicken NK cell responsiveness to interferon stimulation.

    Outcome
    IncreaseNK responsiveness to ChIFN-gamma
    Study

    chickenn: not reported in source

    K and SLD chicken splenocyte-derived NK cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The greatest effect of in vitro thymulin exposure was to increase the responsiveness to NK cells to ChIFN-gamma stimulation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:55 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.